Sugi Predict

Sugi Predict / Targets / TLR8

TLR8

Toll-like receptor 8 · Q9NR97 · TLR8 on Sugi Atlas →

146,758 patent compounds predicted against TLR8, 67,100 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Motolimod Motolimod (SCHEMBL254984) 1.00 20/20
SCHEMBL482958 SCHEMBL482958 1.00 20/20
SCHEMBL233010 SCHEMBL233010 0.66 20/20
SCHEMBL233868 SCHEMBL233868 0.64 20/20
SCHEMBL255417 SCHEMBL255417 0.58 20/20
SCHEMBL162198 SCHEMBL162198 0.50 20/20
SCHEMBL255083 SCHEMBL255083 0.65 16/20
SCHEMBL173639 SCHEMBL173639 0.71 13/20
SCHEMBL317874 SCHEMBL317874 0.62 13/20
SCHEMBL287399 SCHEMBL287399 0.61 13/20
SCHEMBL316709 SCHEMBL316709 0.60 13/20
SCHEMBL317873 SCHEMBL317873 0.60 13/20
Resiquimod Resiquimod (SCHEMBL34159) 1.00 12/20
SCHEMBL255030 SCHEMBL255030 0.75 12/20
SCHEMBL255164 SCHEMBL255164 0.74 12/20
SCHEMBL168398 SCHEMBL168398 0.69 12/20
SCHEMBL195797 SCHEMBL195797 0.50 12/20
SCHEMBL472714 SCHEMBL472714 0.50 12/20
SCHEMBL173461 SCHEMBL173461 0.81 11/20
SCHEMBL211193 SCHEMBL211193 0.61 10/20

Clinical trials — most relevant to TLR8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Reducing Abundance of Human Papilloma Virus in Women by Taking Probiotic PHASE2/PHASE3WITHDRAWN
Clinical Evaluation of the Effect of Metformin in Sepsis PHASE3UNKNOWN
BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors PHASE2COMPLETED
Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients PHASE1/PHASE2COMPLETED
Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients PHASE1/PHASE2COMPLETED
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV PHASE2COMPLETED
Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours PHASE1RECRUITING
RBL001/RBL002 Phase I Clinical Trial PHASE1COMPLETED
The Effects of GLA on Human Volunteers PHASE1COMPLETED
Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) in Healthy Volunteers PHASE1COMPLETED
Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer PHASE1COMPLETED
An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics. PHASE1COMPLETED
Neoadjuvant Imiquimod Immunotherapy for Oral Cancer EARLY_PHASE1COMPLETED
Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19 nanCOMPLETED
Neuro-Immune Interactions in the Gut nanCOMPLETED
Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis). nanUNKNOWN
Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome nanCOMPLETED
Biomarkers of Trained Immunity Following MMR Vaccination nanCOMPLETED
Ventilator-Associated Pneumonia (VAP) in Intensive Care Unit (ICU) nanUNKNOWN
Nasal Immune Challenge Study nanUNKNOWN
Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection nanCOMPLETED
Combined Hemoperfusion and Therapeutic Plasma Exchange for Treatment of Patients With Septic Shock nanCOMPLETED
TLR4 Polymorphisms and Risk of Skin Cancer nanCOMPLETED
Deep Phenotyping of Cutaneous Lupus Erythematosus nanUNKNOWN
The Suppression of Toll Like Receptors by Insulin nanCOMPLETED
Intestinal Genes Expression Associated With Necrotizing Enterocolitis nanUNKNOWN
The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Population nanRECRUITING
Expression of Toll-like Receptors 3 , 7 and 9 in Peripheral Blood Mononuclear Cells of COVID-19 Patients nanUNKNOWN
The Role of Neutrophil CD64 and Soluble Triggering Receptor Expressed on Myeloid Cells 1 in Neonatal Sepsis nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TLR8 binder may also engage these)

ProteinNameSimilarity
P58682 — 1.000 P58682 →
Q9JLF7 — 0.991 Q9JLF7 →
P58681 — 0.988 P58681 →
TLR3 Toll-like receptor 3 0.986 landscape →
Q0PV50 — 0.985 Q0PV50 →
TLR5 Toll-like receptor 5 0.984 landscape →
Q9TSP2 — 0.984 Q9TSP2 →
Q99MB1 — 0.984 Q99MB1 →
Q5TJ59 — 0.983 Q5TJ59 →
Q95M53 — 0.982 Q95M53 →
Q8SPE8 — 0.982 Q8SPE8 →
Q9QX05 — 0.982 Q9QX05 →
Q9BXR5 — 0.981 Q9BXR5 →
B3Y618 — 0.981 B3Y618 →
Q2V898 — 0.981 Q2V898 →
Q9QUK6 — 0.980 Q9QUK6 →
Q9R1F8 — 0.980 Q9R1F8 →
Q9EPQ1 — 0.980 Q9EPQ1 →
Q9GL65 — 0.979 Q9GL65 →
Q6T752 — 0.979 Q6T752 →
Q9TTN0 — 0.979 Q9TTN0 →
Q6R5N8 — 0.979 Q6R5N8 →
TLR4 Toll-like receptor 4 0.979 landscape →
V5NAL9 — 0.979 V5NAL9 →
Q5R482 — 0.979 Q5R482 →
Q689D1 — 0.978 Q689D1 →
E5DHB5 — 0.978 E5DHB5 →
Q68Y56 — 0.978 Q68Y56 →
P21810 — 0.978 P21810 →
P28653 — 0.978 P28653 →